SK284283B6 - Vodná peptidová formulácia, spôsob jej prípravy a jej použitie - Google Patents

Vodná peptidová formulácia, spôsob jej prípravy a jej použitie Download PDF

Info

Publication number
SK284283B6
SK284283B6 SK1798-98A SK179898A SK284283B6 SK 284283 B6 SK284283 B6 SK 284283B6 SK 179898 A SK179898 A SK 179898A SK 284283 B6 SK284283 B6 SK 284283B6
Authority
SK
Slovakia
Prior art keywords
lhrh
leuprolide
formulation
peptide
compound
Prior art date
Application number
SK1798-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK179898A3 (en
Inventor
James B. Eckenhoff (Zosnul�)
Cynthia L. Stevenson
Sally A. Tao
Steven J. Prestrelski
Jeremy C. Wright
Joe Leonard
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of SK179898A3 publication Critical patent/SK179898A3/sk
Publication of SK284283B6 publication Critical patent/SK284283B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SK1798-98A 1996-07-03 1997-07-01 Vodná peptidová formulácia, spôsob jej prípravy a jej použitie SK284283B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2119996P 1996-07-03 1996-07-03
PCT/US1997/010816 WO1998000157A1 (en) 1996-07-03 1997-07-01 Aqueous formulations of peptides

Publications (2)

Publication Number Publication Date
SK179898A3 SK179898A3 (en) 1999-06-11
SK284283B6 true SK284283B6 (sk) 2005-01-03

Family

ID=21802912

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1798-98A SK284283B6 (sk) 1996-07-03 1997-07-01 Vodná peptidová formulácia, spôsob jej prípravy a jej použitie

Country Status (27)

Country Link
US (2) US5916582A (id)
EP (1) EP0909177B1 (id)
JP (2) JP2001504442A (id)
CN (1) CN1256146C (id)
AR (1) AR007715A1 (id)
AT (1) ATE259241T1 (id)
AU (1) AU3574897A (id)
BR (1) BR9710131A (id)
CA (1) CA2259505A1 (id)
CO (1) CO4890855A1 (id)
CZ (1) CZ298464B6 (id)
DE (1) DE69727572T2 (id)
ES (1) ES2213828T3 (id)
HK (1) HK1020677A1 (id)
HU (1) HU225691B1 (id)
ID (1) ID19305A (id)
IL (1) IL127770A (id)
MY (1) MY125556A (id)
NO (1) NO323296B1 (id)
NZ (1) NZ333579A (id)
PL (1) PL189403B1 (id)
RO (1) RO120611B1 (id)
RU (1) RU2201248C2 (id)
SK (1) SK284283B6 (id)
TW (1) TW586932B (id)
WO (1) WO1998000157A1 (id)
ZA (1) ZA975943B (id)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800071B1 (en) 1998-10-29 2004-10-05 Medtronic Minimed, Inc. Fluid reservoir piston
DE69923858T2 (de) 1998-10-29 2006-01-12 Medtronic MiniMed, Inc., Northridge Kompaktes pumpenantriebssystem
US6248093B1 (en) 1998-10-29 2001-06-19 Minimed Inc. Compact pump drive system
US7193521B2 (en) 1998-10-29 2007-03-20 Medtronic Minimed, Inc. Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump
US20020173748A1 (en) 1998-10-29 2002-11-21 Mcconnell Susan Reservoir connector
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7063684B2 (en) 1999-10-28 2006-06-20 Medtronic Minimed, Inc. Drive system seal
MXPA05003318A (es) * 2002-09-27 2005-09-12 Zentaris Gmbh Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos.
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US20060188555A1 (en) * 2005-01-21 2006-08-24 Micheal Cormier Therapeutic peptide formulations with improved stability
US8137664B2 (en) * 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CA2602249C (en) * 2005-04-08 2012-07-10 Amylin Pharmaceuticals, Inc. Peptide and protein formulations with improved stability
CN100336557C (zh) * 2005-05-11 2007-09-12 北京双鹭药业股份有限公司 一种生长抑素的水溶液制剂、其制备方法及应用
US20060293243A1 (en) * 2005-06-17 2006-12-28 Navneet Puri Stable, buffered, pharmaceutical compositions including motilin-like peptides
US20060287243A1 (en) * 2005-06-17 2006-12-21 Navneet Puri Stable pharmaceutical compositions including motilin-like peptides
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009002874A1 (en) 2007-06-22 2008-12-31 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
JP5491396B2 (ja) * 2007-09-11 2014-05-14 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのデフェンシンペプチドの使用
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CN102046192B (zh) * 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 GnRH相关化合物的组合物及制备方法
GEP20156209B (en) 2008-08-15 2015-01-12 Aironvud Farmasiutikalz Ink Linaclotide-containing formulations for oral administration
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
WO2010099255A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
EP2246063A1 (en) * 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
ES2638589T3 (es) 2010-02-17 2017-10-23 Ironwood Pharmaceuticals, Inc. Tratamientos para trastornos intestinales
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
ES2763404T3 (es) 2010-08-11 2020-05-28 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
EP4278996A3 (en) 2015-06-03 2024-01-24 i2o Therapeutics, Inc. Implant placement systems
CN105749245A (zh) * 2016-03-02 2016-07-13 张光泉 抗癌药醋酸地加瑞克注射液及其制备方法
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US4248864A (en) * 1979-08-30 1981-02-03 American Home Products Corporation Reproduction control
EP0111841B1 (en) * 1982-12-10 1987-05-06 Syntex (U.S.A.) Inc. Lhrh preparations for intranasal administration
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
US4851385A (en) * 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
DD273980B5 (de) * 1988-07-12 1994-04-14 Berlin Chemie Ag Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CZ282456B6 (cs) * 1993-06-29 1997-07-16 Ferring B. V. Kompozice pro nasální podání desmopressinu
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
ES2233768T3 (es) * 1996-02-02 2005-06-16 Alza Corporation Liberacion prolongada de un agente activo utilizando un sistema implantable.

Also Published As

Publication number Publication date
CN1224357A (zh) 1999-07-28
HUP0000589A2 (hu) 2000-09-28
EP0909177A1 (en) 1999-04-21
RU2201248C2 (ru) 2003-03-27
NO323296B1 (no) 2007-03-05
US6068850A (en) 2000-05-30
DE69727572T2 (de) 2004-12-16
MY125556A (en) 2006-08-30
US5916582A (en) 1999-06-29
JP2001504442A (ja) 2001-04-03
BR9710131A (pt) 1999-08-10
HUP0000589A3 (en) 2001-04-28
EP0909177B1 (en) 2004-02-11
SK179898A3 (en) 1999-06-11
DE69727572D1 (de) 2004-03-18
HK1020677A1 (en) 2000-05-19
PL330903A1 (en) 1999-06-07
ES2213828T3 (es) 2004-09-01
RO120611B1 (ro) 2006-05-30
CZ433998A3 (cs) 1999-04-14
CN1256146C (zh) 2006-05-17
CZ298464B6 (cs) 2007-10-10
ZA975943B (en) 1998-04-16
PL189403B1 (pl) 2005-08-31
ID19305A (id) 1998-07-02
WO1998000157A1 (en) 1998-01-08
IL127770A (en) 2006-10-31
AU3574897A (en) 1998-01-21
TW586932B (en) 2004-05-11
NO986208L (no) 1998-12-30
ATE259241T1 (de) 2004-02-15
NO986208D0 (no) 1998-12-30
IL127770A0 (en) 1999-10-28
AR007715A1 (es) 1999-11-10
CO4890855A1 (es) 2000-02-28
CA2259505A1 (en) 1998-01-08
HU225691B1 (en) 2007-06-28
NZ333579A (en) 2000-06-23
JP2008291037A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
SK284283B6 (sk) Vodná peptidová formulácia, spôsob jej prípravy a jej použitie
EP0921808B1 (en) Non-aqueous polar aprotic peptide formulations
EP0909175B1 (en) Non-aqueous protic peptide formulations
US5981489A (en) Non-aqueous protic peptide formulations
KR100517091B1 (ko) 펩티드의수성제제
KR100594519B1 (ko) 비수성양성자성펩티드제제
AU2004242540B2 (en) Aqueous formulations of peptides
AU775395B2 (en) Non-aqueous polar aprotic peptide formulations

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20120701